Although gefitinib has been combined successfully with various chemotherapeutic regimens with minimal increase in overall toxicity, experience with concurrent radiation therapy is limited. In this trial, we will evaluate the feasibility, toxicity, and effectiveness a novel combination of chemotherapy, radiation therapy, and gefitinib.
Upon determination of eligibility, patients will receive: Induction Therapy * Docetaxel * Carboplatin * 5-FU * Gefitinib Combined Modality Therapy Cohort 1: * Radiation therapy * Gefitinib Cohort 2: * Radiation therapy * Gefitinib * Docetaxel
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Overall response rate
Overall survival
Time to progression
Overall toxicity
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.